A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH-RISK CUTANEOUS SQUAMOUS CELL CARCINOMA
Study of Cemiplimab in Cutaneous Squamous Cell Carcinoma
Sponsor: Regeneron Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS4125
U.S. Govt. ID: NCT03969004
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is determine if cemiplimab will prevent Cutaneous Squamous Cell Cancer (CSCC) from returning after surgery and radiation.
This study is closed
Investigator
Shaheer Khan, DO
Do You Qualify?
Are you 18 years of age or older? Yes No
Were you diagnosed with Cutaneous Squamous Cell Cancer (CSCC)? Yes No
Are you able to understand and complete study-related questionnaires? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE